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MaOBJECTIVES This study aimed to characterize the use of cardiovascular testing for patients with incident heart failure
(HF) hospitalization who participated in the National Heart, Lung, and Blood Institute sponsored Cardiovascular Research
Network (CVRN) Heart Failure study.
BACKGROUND HF is a common cause of hospitalization, and testing and treatment patterns may differ substantially
between providers. Testing choices have important implications for the cost and quality of care.
METHODS Crude and adjusted cardiovascular testing rates were calculated for each participating hospital. Cox pro-
portional hazards regression models were used to examine hospital testing rates after adjustment for hospital-level
patient case mix.
RESULTS Of the 37,099 patients in the CVRN Heart Failure study, 5,878 patients were hospitalized with incident HF
between 2005 and 2008. Of these, evidence of cardiovascular testing was available for 4,650 (79.1%) patients between
14 days before the incident HF admission and ending 6 months after the incident discharge. We compared crude and
adjusted cardiovascular testing rates at the hospital level because the majority of testing occurred during the incident HF
hospitalization. Of patients who underwent testing, 4,085 (87.9%) had an echocardiogram, 4,345 (93.4%) had a systolic
function assessment, and 1,714 (36.9%) had a coronary artery disease assessment. Crude and adjusted testing rates
varied markedly across the proﬁled hospitals, for individual testing modalities (e.g., echocardiography, stress echocar-
diography, nuclear stress testing, and left heart catheterization) and for speciﬁc clinical indications (e.g., systolic function
assessment and coronary artery disease assessment).
CONCLUSIONS For patients with newly diagnosed HF, we did not observe widespread overuse of cardiovascular
testing in the 6 months following incident HF hospitalization relative to existing HF guidelines. Variations in testing
were greatest for assessment of ischemia, in which testing guidelines are less certain. (J Am Coll Cardiol Img
2014;7:690–700) © 2014 by the American College of Cardiology Foundation.m the *Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois;
epartment of Management and Strategy, Kellogg School of Management, Evanston, Illinois; zInstitute for Health Research,
iser Permanente Colorado, Denver, Colorado; xMeyers Primary Care Institute, Worcester, Massachusetts; kDivision of Geriatric
dicine, University of Massachusetts Medical School, Worcester, Massachusetts; {Center for Health Research, Kaiser Perma-
nte Northwest, Portland, Oregon; #Division of Research, Kaiser Permanente of Northern California, Oakland, California;
epartments of Epidemiology, Biostatistics, and Medicine, University of California, San Francisco, San Francisco, California; and
yyDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, California. This study was
nducted within the Cardiovascular Research Network, sponsored by the National Heart, Lung, and Blood Institute (NHLBI)
19 HL91179-01) and the American Recovery and Reinvestment Act of 2009 (NHLBI Grant #1RC1HL099395-01). Dr. Smith has
eived a grant from Sanoﬁ Pasteur to study C. difﬁcile infection. All other authors have reported that they have no relationships
evant to the contents of this paper to disclose.
nuscript received February 14, 2014; accepted February 20, 2014.
ABB R E V I A T I O N S
AND ACRONYMS
ACC = American College of
Cardiology
ACR = American College of
Radiology
AHA = American Heart
Association
AUC = appropriate use criteria
CAD = coronary artery disease
CTA = computed tomography
angiography
CMR = cardiac magnetic
resonance
CMS = Centers for Medicare
and Medicaid Services
CVRN = Cardiovascular
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691O ver the past several decades, advances inthe prevention and treatment of cardiovas-cular disease have led to important de-
clines in age-adjusted, cardiovascular-related
mortality (1). At the same time, cardiovascular imag-
ing has proliferated (2,3). A recent review of Medicare
billing data revealed a doubling of expenditures on
medical imaging, from $6.89 billion in 2000 to $14.1
billion in 2005, approximately one-third of this
involved cardiovascular imaging (4). Medicare ex-
penditures for diagnostic imaging have grown more
rapidly than any other component of medical care (5).
However, relatively few data link cardiovascular im-
aging to improved patient outcomes, and concern is
growing that these tests have been adopted at
extraordinary cost with insufﬁcient evidence of
beneﬁt (6,7).SEE PAGE 701
Research Network
HF = heart failure
MPI = myocardial perfusion
imaging
NHLBI = National Heart, Lung,
and Blood Institute
PET = positron emission
tomography
SPECT = single-photon
emission tomography
TEE = transesophageal
echocardiography
TTE = transthoracic
echocardiographyIn response to this dramatic growth in imaging,
professional groups have promulgated clinical prac-
tice guidelines and appropriate use criteria (AUC)
(8–12). However, the AUC are not supported by
randomized trial evidence, and guidelines rarely
consider cost effectiveness (13). AUC are limited in
their discussion of how multiple testing modalities
are most efﬁciently combined where multiple over-
lapping testing indications exist. Noninvasive imag-
ing techniques may be interchangeable in some
instances, and diminishing returns to overlapping
imaging studies are likely. Therefore, there is a crit-
ical need to better understand how imaging combi-
nations are used in clinical practice.
There are more than 1 million hospitalizations for
acute heart failure (HF) annually, and the inpatient
cost for these patients was estimated at $20.1 billion
in 2009 (1,14). Testing and treatment patterns for
newly diagnosed HF may differ substantially be-
tween providers and may have important implica-
tions for the cost and quality of care (15–17). In this
study, we describe the type and frequency of car-
diovascular testing in the ﬁrst 6 months following
hospitalization for incident HF in a large, diverse
cohort of patients derived from the Cardiovascular
Research Network (CVRN) Heart Failure study.
METHODS
SOURCE POPULATION. The source population in-
cluded members from 3 participating health plans
within the National Heart, Lung, and Blood Institute
(NHLBI) sponsored CVRN (1,18,19). Sites included
hospitals participating in the Kaiser Permanente
Northern California, Kaiser Permanente Colorado,and Kaiser Permanente Northwest regions.
These sites are integrated healthcare delivery
systems that provide comprehensive care
to ethnically, socioeconomically, and geo-
graphically diverse populations across vari-
ous practice settings. They systematically
track care provided and outcomes experi-
enced within and outside of owned facilities.
Each site has a virtual data warehouse that
serves as the primary data source for patient
identiﬁcation and characterization (19). The
virtual data warehouses are comprised of
electronic datasets populated with linked
demographic, administrative, and healthcare
utilization data. Utilization data include am-
bulatory visits, as well as network and non-
network hospitalizations with diagnoses and
procedures. Institutional review boards at
participating sites approved the study.
Study sample. We identiﬁed all persons
aged $21 years who were hospitalized with
newly diagnosed HF from 2005 to 2008. We
used the following International Classiﬁca-
tion of Diseases-9th Edition (ICD-9) codes:
398.91, 402.01, 402.11, 402.91, 404.01, 404.03,
404.11, 404.13, 404.91, 404.93, 428.0, 428.1,
428.20, 428.21, 428.22, 428.23, 428.30, 428.31,
428.32, 428.33, 428.40, 428.41, 428.42, 428.43,
and 428.9. Previous studies showed a posi-
tive predictive value of >95% for admis-
sions with a primary discharge diagnosis of HF on
the basis of these codes compared with chart review
and Framingham clinical criteria (20–22). Hospital-
izations for HF were identiﬁed from each site’s
virtual data warehouse on the basis of a primary
ICD-9 discharge diagnosis for HF. We deﬁned inci-
dent HF as an eligible HF hospitalization within the
sampling frame that was not preceded by any other
inpatient or outpatient HF diagnosis within the
previous 5 years.
We excluded patients who did not have continuous
health plan membership and pharmacy drug beneﬁts
during the 12 months before their index HF admis-
sion. We excluded patients who did not have at least
1 outpatient visit within 3 months of their index HF
admission to ensure more complete data on post-
discharge medical care. Finally, we excluded pa-
tients with a diagnosis of systemic cancer, because
serial imaging may be indicated to assess the safety of
chemotherapy administration, even in the absence of
symptomatic HF (Fig. 1) (8,23).
We identiﬁed all cardiovascular testing that
occurred between 14 days before and 180 days
after the incident HF hospitalization. Administrative
FIGURE 1 Cohort Assembly for Patients With Incident Heart Failure From the CVRN Heart Failure Study
CVRN ¼ Cardiovascular Research Network.
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692records were searched for any evidence of testing.
Imaging reports were also searched for evidence of an
associated report from an imaging study that was
performed despite no available administrative bill.
For cases where no evidence of testing was iden-
tiﬁed through either administrative records or study
report, the medical record was manually reviewed
to identify if any testing occurred. This procedure
was intended to capture studies that may have been
performed at another hospital. Cardiovascular test-
ing included transthoracic echocardiography (TTE),
transesophageal echocardiography (TEE), stress
echocardiography, single-photon emission computed
tomography (SPECT), positron emission tomography
(PET), cardiac magnetic resonance (CMR) imaging,
nuclear scintigraphy, left ventriculography, left heart
catheterization, right and left heart catheterization,
and cardiac computed tomography angiography
(CTA). We considered all tests performed between
14 days before and 30 days after the incident HF
admission to represent the initial testing strategy. We
included testing before the index admission because
outpatient testing may have prompted the indexhospitalization. The Centers for Medicare & Medicaid
Services (CMS) use a similar rationale to bundle pay-
ment for HF episodes of care in their Bundled Pay-
ments for Care Initiative (24). A systolic function
assessment included any of the following tests
individually or in combination: TTE, TEE, stress
echocardiography, SPECT, PET, CMR, nuclear scin-
tigraphy, or left ventriculography. A coronary artery
disease (CAD) assessment included stress echocardi-
ography, SPECT, PET, left heart catheterization, right
and left heart catheterization, or cardiac CTA.
Administrative data were searched for the following
procedural codes: 76620, 76625, 76627, 76628, 76632,
93303, 93304, 93306, 93307, 93308, 93320, 93321,
93325, X3307, 7662A, 7662B, 7662C, 7662D, 7662E,
7662F, 7662G, 7663A, 7663B, 9331B, 9332A, X3308,
93350, 93312, 93313, 93314, 93318, 9331A, X3312,
93510, 93511, 93539, 93540, 93545, 93543, 75552,
75553, 75554, 75555, 75556, 75557, 75558, 75559, 75560,
75561, 75562, 75563, 75564, 78496, 78459, 78491,
78492, 93526, 78464, 78465, 78468, 78469, 78472,
78473, 78478, 78480, 78481, 78483, 78494, 93015,
93016, 93017, and 93018.
TABLE 1 Baseline Characteristics Among Patients Hospitalized for Incident HF (2005 to 2008)
Overall
(N ¼ 5,878)
Imaging Test Available
(n ¼ 4,650)
Imaging Test Not Available
(n ¼ 1,228) p Value
Age, yrs 73.4  13.8 72.2  13.9 78.1  12.6 <0.001
Female 3,039 (51.7) 2,319 (49.9) 720 (58.6) <0.001
Medical history
Acute myocardial Infraction 350 (6.0) 239 (5.1) 111 (9.0) <0.001
Unstable angina 193 (3.3) 140 (3.0) 53 (4.3) 0.02
Coronary artery bypass surgery 169 (2.9) 131 (2.8) 38 (3.1) 0.61
Percutaneous coronary intervention 318 (5.4) 239 (5.1) 79 (6.4) 0.07
Ischemic stroke or transient ischemic attack 421 (7.2) 296 (6.4) 125 (10.2) <0.001
Cerebrovascular disease 977 (16.6) 710 (15.3) 267 (21.7) <0.001
Other thromboembolic event 37 (0.6) 25 (0.5) 12 (1.0) 0.08
Atrial ﬁbrillation or atrial ﬂutter 1,744 (29.7) 1,294 (27.8) 450 (36.6) <0.001
Ventricular ﬁbrillation or ventricular tachycardia 85 (1.4) 68 (1.5) 17 (1.4) 0.84
Mitral and/or aortic valvular disease 728 (12.4) 510 (11.0) 218 (17.8) <0.001
Peripheral arterial disease 418 (7.1) 302 (6.5) 116 (9.4) <0.001
Rheumatic heart disease 179 (3.0) 142 (3.1) 37 (3.0) 0.94
Cardiac resynchronization therapy 3 (0.1) 2 (0.0) 1 (0.1) 0.60
Implantable cardioverter deﬁbrillator 28 (0.5) 24 (0.5) 4 (0.3) 0.39
Pacemaker 202 (3.4) 141 (3.0) 61 (5.0) 0.001
Dyslipidemia 3,481 (59.2) 2,741 (58.9) 740 (60.3) 0.40
Hypertension 4,536 (77.2) 3,484 (74.9) 1052 (85.7) <0.001
Diabetes mellitus 1,079 (18.4) 845 (18.2) 234 (19.1) 0.48
Hospitalized bleeds 291 (5.0) 200 (4.3) 91 (7.4) <0.001
Chronic lung disease 2,037 (34.7) 1,583 (34.0) 454 (37.0) 0.06
Chronic liver disease 212 (3.6) 173 (3.7) 39 (3.2) 0.36
Baseline estimated GFR category <0.001
>130 13 (0.2) 10 (0.2) 3 (0.2)
90–130 703 (12.0) 610 (13.1) 93 (7.6)
60–89 2,107 (35.8) 1,704 (36.6) 403 (32.8)
45–59 1,255 (21.4) 967 (20.8) 288 (23.5)
30–44 831 (14.1) 601 (12.9) 230 (18.7)
15–29 343 (5.8) 250 (5.4) 93 (7.6)
<15 64 (1.1) 52 (1.1) 12 (1.0)
Dialysis 150 (2.6) 87 (1.9) 63 (5.1)
Missing 412 (7.0) 369 (7.9) 43 (3.5)
Baseline estimated hemoglobin category <0.001
$16.0 343 (5.8) 299 (6.4) 44 (3.6)
15.0–15.9 503 (8.6) 419 (9.0) 84 (6.8)
14.0–14.9 924 (15.7) 747 (16.1) 177 (14.4)
13.0–13.9 1,083 (18.4) 846 (18.2) 237 (19.3)
12.0–12.9 1,006 (17.1) 777 (16.7) 229 (18.6)
11.0–11.9 689 (11.7) 502 (10.8) 187 (15.2)
10.0–10.9 455 (7.7) 339 (7.3) 116 (9.4)
9.0–9.9 182 (3.1) 131 (2.8) 51 (4.2)
<9.0 107 (1.8) 76 (1.6) 31 (2.5)
Missing 586 (10.0) 514 (11.1) 72 (5.9)
Systolic blood pressure category, mm Hg 0.02
$180 250 (4.3) 201 (4.3) 49 (4.0)
160–179 571 (9.7) 430 (9.2) 141 (11.5)
140–159 1,332 (22.7) 1,038 (22.3) 294 (23.9)
130–139 1,294 (22.0) 1,038 (22.3) 256 (20.8)
121–129 857 (14.6) 686 (14.8) 171 (13.9)
110–120 1,100 (18.7) 866 (18.6) 234 (19.1)
100–109 211 (3.6) 168 (3.6) 43 (3.5)
<100 90 (1.5) 69 (1.5) 21 (1.7)
Missing 173 (2.9) 154 (3.3) 19 (1.5)
Continued on the next page
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TABLE 1 Continued
Overall
(N ¼ 5,878)
Imaging Test Available
(n ¼ 4,650)
Imaging Test Not Available
(n ¼ 1,228) p Value
Diastolic blood pressure category, mm Hg <0.001
$110 110 (1.9) 98 (2.1) 12 (1.0)
100–109 197 (3.4) 161 (3.5) 36 (2.9)
90–99 475 (8.1) 387 (8.3) 88 (7.2)
85–89 370 (6.3) 304 (6.5) 66 (5.4)
81–84 457 (7.8) 371 (8.0) 86 (7.0)
#80 4,096 (69.7) 3,175 (68.3) 921 (75.0)
Missing 173 (2.9) 154 (3.3) 19 (1.5)
HDL cholesterol category, g/dl 0.25
$60 1,057 (18.0) 809 (17.4) 248 (20.2)
50–50.9 1.046 (17.8) 840 (18.1) 206 (16.8)
40–49.9 1.471 (25.0) 1.167 (25.1) 304 (24.8)
35–39.9 698 (11.9) 546 (11.7) 152 (12.4)
<35 720 (12.2) 577 (12.4) 143 (11.6)
Missing 886 (15.1) 711 (15.3) 175 (14.3)
LDL cholesterol category, g/dl 0.12
$200 62 (1.1) 55 (1.2) 7 (0.6)
160–199.9 263 (4.5) 206 (4.4) 57 (4.6)
130–159.9 668 (11.4) 522 (11.2) 146 (11.9)
100–129.9 1.362 (23.2) 1.087 (23.4) 275 (22.4)
70–99.9 1.789 (30.4) 1.411 (30.3) 378 (30.8)
<70 798 (13.6) 610 (13.1) 188 (15.3)
Missing 936 (15.9) 759 (16.3) 177 (14.4)
Values are mean  SD or n (%).
GFR ¼ glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
FIGURE 2 Frequency of Cardiovascular Testing Between 14 Days Before
and 180 Days Following the Incident Heart Failure Admission
Pareto chart of cardiovascular testing (in days) from 14 days before the
incident heart failure admission through 180 days following the incident heart
failure admission. The frequency of testing is represented in the bar charts.
The cumulative percent of testing is represented in the plot.
Farmer et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 7 , 2 0 1 4
Variation in Testing for Incident HF J U L Y 2 0 1 4 : 6 9 0 – 7 0 0
694We identiﬁed hospital characteristics from the
American Heart Association (AHA) Hospital Statis-
tics for 2009 (25). We ascertained characteristics
of hospitals not included in the AHA database
by manually calling hospital administrators at the
included sites.
COVARIATES. Information on coexisting illnesses
was on the basis of relevant ICD-9 and Current Proce-
dural Terminology codes, laboratory results, or ﬁlled
outpatient prescriptions from health plan pharmacy
databases. We chose laboratory values closest to the
index date. Information was also obtained from site-
speciﬁc cancer registries (26). We collected baseline
data on diagnoses of acute myocardial infarction,
unstable angina, coronary artery revascularization,
hypertension, diabetes mellitus, chronic lung disease,
and systemic cancer on the basis of ICD-9 and Current
Procedural Terminology codes (26).
Statistical analysis. All analyses were conducted using
SAS statistical software, version 9.3 (SAS Institute,
Cary, North Carolina). Because most cardiovascular
testing occurred during the incident HF hospitaliza-
tion, the hospital was designated as the unit of
analysis. To create statistically valid hospital testing
proﬁles, we restricted the analysis to the 31 hospitals
TABLE 2 Frequency of Testing Combinations Used for Patients
With Incident Heart Failure
Echo 2,453 (52.8)
Stress Echo þ SPECT 528 (11.4)
Echo þ SPECT 244 (5.2)
SPECT 212 (4.6)
Stress Echo 212 (4.6)
RHC þ LHC 148 (3.2)
LHC 146 (3.1)
Echo þ LHC 141 (3.0)
Echo þ RHC þ LHC 122 (2.6)
Other 441 (9.5)
Values are n (%).
Echo ¼ transthoracic echocardiogram; LHC ¼ left heart catheterization;
RHC ¼ right heart catheterization; SPECT ¼ single-photon emission computed
tomography; Stress Echo ¼ stress echocardiogram or dobutamine stress
echocardiogram.
TABLE 3 Frequency and Timing of Hospital Readmissions
30-day hospital readmission 712 (12.1)
180-day hospital readmission 2,236 (38.0)
Frequency of hospital readmission
0 3,642 (62.0)
1 1,378 (23.4)
2 507 (8.6)
3 228 (3.9)
$4 123 (2.1)
Values are n (%).
TABLE 4 Testing Rates for Individual Testing Modalities
Crude Rate per
100 Patient-Years
Adjusted Rate per
100 Patient-Years
Echocardiography 24.8–62.0 22.3–161.8
Stress echocardiography 3.1–27.9 3.5–37.2
SPECT 3.1–27.9 1.3–63.9
LHC 5.8–27.4 9.3–63.4
Abbreviations as in Table 2.
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695with a minimum of 40 incident HF admissions. This
threshold was chosen because 96.7% of cardiovascular
tests were performed in these 31 hospitals, and the
number of incident HF admissions per hospital drop-
ped sharply below this cutpoint (data not shown).
Crude and adjusted cardiovascular testing rates were
calculated for each hospital in the ﬁnal dataset. Cox
proportional hazards regression models were used to
examine hospital testing rates after adjustment for
hospital-level patient case mix and to account for
differential time of follow-up and censoring. Patients
who died, disenrolled, ended participation in the
CVRN Heart Failure study, or had a transplant were
censored. Adjusted hospital testing rates were
compared with the facility that had the highest rate of
echocardiography testing. Case mix was deﬁned using
administrative data. Covariates included age, sex,
diabetes, hypertension, dyslipidemia, coronary dis-
ease, and end-stage renal disease.
RESULTS
Of the 37,099 patients included in the CVRN Heart
Failure study, we identiﬁed 5,878 patients hospital-
ized for incident HF between 2005 and 2008. Of
these, cardiovascular testing was performed for
4,650 (79.1%) patients beginning 14 days before the
incident HF admission and ending 6 months after
discharge. Patients with and without testing differed
from each other in a number of important respects.
Patients with identiﬁable testing were younger,
more likely to be men, and had fewer comorbidities
(Table 1). For those patients with available testing,
the majority of tests were completed during or
immediately following the index HF admission
(Fig. 2).All but 2 of the hospitals were not-for-proﬁt, and
13 (42%) were teaching facilities. Eighteen (58%)
offered on-site cardiac catheterization, and 17 (55%)
offered on-site cardiac surgery. All hospitals without
onsite cardiac catheterization had referral agree-
ments with centers that offered this service. The
mean  SD hospital bed size was 165.8  99.1, with
median of 150 (interquartile range: 96.2). Median
household income for the county in which the hos-
pital was located ranged from $41,390 to $78,009. All
but 3 hospitals were located in counties above the
median household income nationwide ($46,326) and
all in counties below the 80th percentile. Twenty-
four of the hospitals were located in California, 3
were located in Oregon, 2 were located in Colorado,
and 2 were located in Washington state.
For patients with available results, 4,085 (87.9%)
had an echocardiogram, 4,345 (93.4%) had a systolic
function assessment, and 1,714 (36.9%) had a CAD
assessment. A total of 1,213 (26.1%) had multiple tests
during the study (Table 2). Repeat testing was infre-
quent in the 6 months following incident HF admis-
sion across all sites. Between 30 and 180 days after
their incident HF admission, only 51 (1.1%) patients
had a repeat echocardiogram and 677 (14.6 %)
patients had any additional cardiovascular test. The
rate of repeat testing was low, although 712 (12.1%)
patients were readmitted within 30 days following
discharge and 2,236 (38.0%) patients were readmitted
within 6 months following discharge (Table 3). Only
FIGURE 3 Adjusted Hazard Ratio and 95% Conﬁdence Interval of Any
Cardiovascular Test Use Among 5,878 Adults With Incident Heart
Failure by Hospital (2005 to 2008)
Adjusted hazard ratio of cardiovascular testing relative to the hospital with
the highest rate of echocardiography.
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1 test performed during the study.
Crude testing proportions varied substantially
across the hospitals for individual testing modalities
and for testing by indication; these differences per-
sisted following multivariable adjustment for poten-
tial confounders (Table 4). When all testing methods
were considered together, rates of systolic function
assessment ranged from 53.9 to 242.7 per 100 patient-
years (adjusted hazard ratio: 0.69 to 1.29), and rates
of ischemia assessment ranged from 31.1 to 140.5 per
100 patient-years (adjusted hazard ratio: 0.76 to 1.98)
(Figs. 3 to 5).
DISCUSSION
In this study, we examined hospital-level varia-
tions in the use of cardiovascular testing for patients
hospitalized for incident HF. To our knowledge, noprevious published study has comprehensively ex-
amined patterns of use of all major testing modalities
simultaneously among newly diagnosed HF patients.
Similar to previous work on geographic variations
in healthcare utilization, our ﬁndings demonstrate
wide hospital variations in testing (27,28). Our study
extends previous work by assessing both individual
testing modalities and clinical indications (e.g.,
assessment of systolic function, assessment of CAD)
in adults with incident HF.
One of the 4 core HF performance measures pro-
moted by the Joint Commission is the “documentation
in the hospital record that left ventricular systolic
function was evaluated before arrival, during hospi-
talization, or is planned for after discharge” (29).
Recent Medicare reimbursement reductions for out-
patient echocardiography and nuclear stress testing
reﬂect a widespread belief that these tests are gener-
ally overused (30,31). However, we found <1 evalua-
tion of systolic function per patient, very low rates of
multiple testing, and very infrequent repeat testing in
the initial 6 months following incident HF hospitali-
zation within the participating healthcare delivery
systems. Our ﬁndings do not represent overuse rela-
tive to existing HF guidelines for systolic function
assessment (32).
Echocardiography is the mainstay of systolic
function assessment in incident HF and carries
both an American College of Cardiology (ACC)/AHA
class IC recommendation (11) and an “appropriate”
rating in the American College of Radiology (ACR)/
ACC report on appropriate use of cardiovascular
imaging in HF (33). Although a recent study sug-
gests that even clinically appropriate studies may
not be clinically useful, a complete evaluation of
HF requires an assessment of cardiac structure
and function, which involves imaging (34,35). The
results of imaging are essential for selection of
evidence-based therapies for HF and are useful for
prognostication (36,37). Although the sensitivity and
speciﬁcity of ICD-9-Clinical Modiﬁcation codes is
imperfect, not all patients in this cohort appeared
to have received an echocardiogram during the
ascertainment window of interest. Furthermore,
both crude and adjusted rates of echocardiography
differed substantially among the 31 hospital sites
proﬁled.
Repeat echocardiographic assessment may be ap-
propriate when there is a change in clinical status, for
assessment of response to medical therapy, and to
determine eligibility for advanced HF interventions,
such as implantable cardioverter deﬁbrillators or
biventricular pacing (38). In this study, 38% of pa-
tients were readmitted during follow-up, and some
FIGURE 4 Adjusted Hazard Ratio and 95% Conﬁdence Interval of
Systolic Assessment Test Use Among 4,650 Adults With Incident
Heart Failure and at Least One Available Imaging Test by Hospitals
(2005 to 2008)
Adjusted hazard ratio of cardiovascular testing relative to the hospital with
the highest rate of echocardiography. A systolic function assessment included
any of the following tests individually or in combination: echocardiography,
transesophageal echocardiography, stress echocardiography, single-photon
emission computed tomography; positron emission tomography, cardiac
magnetic resonance, nuclear scintigraphy, or left ventriculography.
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697of these hospitalizations may have represented a
change in clinical status that justiﬁed additional
cardiovascular testing (39). Even so, there was a very
low rate of repeat imaging for readmitted patients in
this cohort, and only 1.1% of patients overall had a
repeat echocardiogram during short-term follow-up
despite a high rate of hospital readmissions. This low
rate of repeat testing may reﬂect the advanced elec-
tronic medical record available in all participating
health systems, which readily provided previous
imaging results, strong incentives to be treated
within a network facility, and close follow-up that
characterized the integrated healthcare delivery
model.
In this patient population, there was signiﬁcantly
more variation in rates of assessment of CAD than
for assessment of systolic function. Although not
codiﬁed as a quality measure by the Joint Com-
mission, performance of coronary arteriography to
exclude CAD as the basis of left ventricular systolic
function is an ACC/AHA Class IB recommendation
for patients with known or suspected CAD (11,12).
The indications for CAD assessment in patients
without clinical, electrocardiographic, or imaging
ﬁndings of CAD are uncertain (9,11,12,33,40). The
lack of high-quality evidence has led to imprecise
use of cardiovascular imaging in this clinical situa-
tion. Not surprisingly, there was marked between-
hospital variation in the rate and method of
ischemia assessment. Differences in test availability
and physician expertise between hospital sites may
have played a role in variability of ischemia testing,
particularly for cardiac catheterization. Several testing
types were rarely used, including PET, CMR, and car-
diac CTA. However, stress echocardiography and
stress SPECT testing are commonly available, and
although most testing occurred during the inci-
dent hospitalization, our testing proﬁles extended
to 6 months following incident diagnosis; therefore,
all patients had access to cardiac catheterization.
Although all patients in this cohort had access to car-
diac catheterization within the network, the avail-
ability of left heart catheterization at the presenting
hospital may have inﬂuenced test selection. We were
unable to identify which patients had signs, symp-
toms, or ﬁndings of ischemia on initial testing and
who were most likely to beneﬁt from an ischemia
evaluation.
The ACR/ACC appropriate utilization of cardiovas-
cular imaging in HF guidelines supports a sequential
testing approach in newly diagnosed HF. Even so,
few patients underwent multiple testing in this
patient population. Different cardiovascular testing
approaches offer overlapping information, are notclinically interchangeable, and differ considerably
with regard to cost and invasiveness. Each modality
offers unique information, and a variety of testing
combinations are possible, with considerable impli-
cations for cost and cost effectiveness. We were
unable to assess why 11.4% of patients underwent
both a stress echocardiogram and a SPECT study. This
combinationmay reﬂect poor endocardial deﬁnition or
failure to reach the target heart rate on the stress
echocardiogram, but could also reﬂect perceived
complementarity between these tests. Also, we did not
search records for exercise treadmill testing without
imaging, and the rates of ischemic evaluation may
therefore be higher than those reported here. Further
FIGURE 5 Adjusted Hazard Ratio and 95% Conﬁdence Interval of CAD
Test Use Among 4,650 Adults With Incident Heart Failure and at Least
One Available Imaging Test by Hospitals (2005 to 2008)
Adjusted hazard ratio of cardiovascular testing relative to the hospital with
the highest rate of echocardiography. A coronary artery disease assessment
included: stress echocardiography, single-photon emission computed to-
mography; positron emission tomography, left heart catheterization, right and
left heart catheterization, or cardiac computed tomographic angiography.
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698study is needed to determine the most cost-effective
approach to initial assessment of incident HF, partic-
ularly where CAD is suspected.
STUDY LIMITATIONS. The CVRN Heart Failure
cohort offers a source of “real world” data for a large
and diverse patient cohort that was hospitalizedfor incident HF. However, because the majority of
patients were treated within integrated healthcare
delivery systems with comprehensive coverage
plans for many patients, some imaging studies that
were actually performed may not have been coded
in the electronic databases. To minimize this po-
tential bias, we augmented our analysis of admin-
istrative procedure coding data with a review of
imaging speciﬁc reports and a manual review of
patient records. Even so, some cardiovascular
testing may have been performed without gener-
ating a formal report (e.g., bedside-limited echocar-
diogram) or documentation, and some tests may not
have been available in any of the data sources used.
We were unable to identify the reasons behind the
testing variations seen in this study. Further, all
patients in our sample had health insurance,
including a pharmacy drug beneﬁt and the avail-
ability of advanced electronic medical record sys-
tems, which may have substantially reduced
duplicate testing. Therefore, these ﬁndings may not
be generalizable to other patient populations and
settings. However, extensive national investments
in electronic medical records with “meaningful use”
(41) and pilot programs in “accountable care” may
mitigate these historical differences (24,42,43).
CONCLUSIONS
In a contemporary population of adults hospitalized
for incident HF, we found signiﬁcant hospital-level
variations in cardiovascular testing that did not
appear to be explained by patient case mix. The
greatest variations occurred in testing modalities for
CAD, in which less rigorous evidence exists for their
clinical utility. More research is needed to clarify the
most cost-effective test or testing combination for
patients with incident HF.
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